Minocycline
Minocycline, second-generation tetracycline antibiotic
Written by Aaron CuhaReviewed Sep 2026
Also known as: Minocin, Solodyn
No change in mouse survival in either sex in the National Institute on Aging's late-life cohort. In a 412-person ALS trial it made patients worse, and in 544 people with mild Alzheimer's over two years it changed nothing.
Overview
Minocycline arrived in ageing research on the strength of a good story. It crosses the blood brain barrier, it suppresses microglial activation, it is anti-apoptotic in vitro, and it extended survival in mouse models of several neurological diseases. For roughly a decade it was among the most-trialled repurposing candidates in neurology.
The Interventions Testing Program tested it in the cohort designed around late-life rapamycin dosing, alongside beta-guanidinopropionic acid, MitoQ and 17-DMAG. Rapamycin started at 20 months extended survival. None of the other four drugs changed survival in either sex.
The human neurological record is worse than null. In a 412-patient phase III trial in amyotrophic lateral sclerosis, function on the ALSFRS-R scale declined faster on minocycline than on placebo, -1.30 against -1.04 units per month, p equals 0.005, with non-significant trends toward faster loss of vital capacity and higher mortality. The authors stated plainly that minocycline had a harmful effect and that this had implications for the other neurological trials then running.
One of those trials reported in 2020. In 544 people with mild Alzheimer's disease randomised to 200 mg, 400 mg or placebo for 24 months, decline in the standardised Mini-Mental State Examination was 4.1 points on minocycline against 4.3 on placebo. No benefit, and the 400 mg arm was so poorly tolerated that only 28.8 percent completed it.
What minocycline does do, reliably, is treat acne. A Cochrane review of 39 randomised trials in 6,013 participants found it effective for moderate inflammatory acne, with no evidence that it beats the cheaper alternatives, and with a distinctive safety concern of its own.
Mechanism of action
A tetracycline that binds the bacterial 30S ribosomal subunit and blocks aminoacyl-tRNA docking, which is its antibiotic action. Its non-antibiotic properties are the reason it was tested for ageing and neuroprotection: it is lipophilic enough to enter the central nervous system, it inhibits microglial activation and matrix metalloproteinases, and it interferes with caspase-dependent apoptosis and cytochrome c release in cell models. Those effects are real in vitro. The ALS trial is the clearest demonstration on this site that a mechanism confirmed in cells and in disease-model mice can translate into net harm in patients.
Human evidence
Substantial, and mostly negative outside dermatology. Two large neurological trials, one showing harm and one showing nothing, against a Cochrane-confirmed but unremarkable benefit in acne.
- ALS, 412 patients: functional decline was significantly faster on minocycline than placebo, with the trial authors describing the effect as harmful.
- Mild Alzheimer's disease, 544 patients over 24 months: no difference in cognition or daily function at either dose.
- Acne vulgaris, 39 trials and 6,013 participants: effective, but not better than cheaper alternatives.
- Minocycline specifically, and not other tetracyclines, is associated with drug-induced lupus, at about 8.8 cases per 100,000 person-years, with risk rising the longer it is taken.
- Irreversible skin and mucosal pigmentation is a recognised effect of long-term use and is part of why its first-line acne role has narrowed.
- No human study has examined lifespan, healthspan or any geroscience endpoint.
What this does not tell you: There is no human ageing data at all. What the human record supplies instead is a caution about the mechanism: the same anti-inflammatory, anti-apoptotic properties that made minocycline a lifespan candidate were tested directly in a neurodegenerative disease and the treated group did worse. That does not transfer automatically to healthy people at lower doses, and it is the most relevant safety information available.
Reading the research record
A lifespan null from this programme is a real, expensive, well-powered finding, and it is narrower than it sounds. What was tested was one concentration in the diet, started at one age, in one mouse strain, with death as the endpoint. A null tells you that this dose, in these animals, did not move that endpoint. It does not tell you the compound is inert, that a different dose would also fail, that the mechanism is wrong, or that the reason people actually take it has been refuted. Those are separate questions and most of them were never asked. The failure mode this site is trying to avoid runs in both directions: treating a mouse lifespan positive as proof that a supplement works, and treating a mouse lifespan null as proof that it does nothing.
Minocycline is the entry where the null is the least interesting finding on the page. A mouse lifespan study that shows nothing leaves the question open. A 412-person randomised trial in which the treated group declined significantly faster does not.
It is also a case study in how a mechanism accumulates credibility without ever being tested where it matters. Minocycline suppressed microglial activation in vitro, protected neurons in culture, and extended survival in disease-model mice, and on that basis it entered trials in ALS, Parkinson's disease, multiple sclerosis, stroke and Alzheimer's disease. The two largest of those to report found harm and nothing respectively. The ITP lifespan null arrived later and is consistent with both.
The Interventions Testing Program is funded by the National Institute on Aging and run in parallel at three independent laboratories, in Bar Harbor, Ann Arbor and San Antonio. It uses UM-HET3 mice, a four-way genetic cross, so no result can be an artefact of a single inbred background. Both sexes are studied, cohorts are sized to detect roughly a 10 percent shift in lifespan, compounds are fed in the diet from a stated starting age, and the programme commits in advance to publishing negative results alongside positive ones. That last commitment is why this batch can exist at all: almost no other part of ageing research reliably tells you what did not work.
The evidence, charted
Fig. 1 · evidence composition
2of 4 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2007 to 2020, counted from the citation list on this page. The newest citation on file is from 2020, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2020
Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects
Interventions Testing Program cohort comparing three late-life rapamycin regimens started at 20 months. Rapamycin at 42 ppm increased survival in both sexes. The same experimental design tested four other drugs, minocycline, beta-guanidinopropionic acid, MitoQ and 17-DMAG, and none of these led to a change in survival in either sex.
Aging Cell - Human2007
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
412 patients randomised to placebo or escalating minocycline up to 400 mg per day for nine months. ALSFRS-R deterioration was faster on minocycline, -1.30 against -1.04 units per month (p equals 0.005), with non-significant trends toward faster decline in forced vital capacity and muscle testing and greater mortality (hazard ratio 1.32). The authors concluded minocycline had a harmful effect with implications for its trials in other neurological disorders.
Lancet Neurology - Human2020
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial
554 randomised, 544 analysed, across 32 NHS memory clinics, 24 months of 400 mg, 200 mg or placebo. Standardised MMSE decline was 4.1 points in the combined minocycline groups against 4.3 on placebo, a difference of 0.1 points (95 percent CI -1.1 to 1.2, p equals 0.90). Activities of daily living worsened equally. Only 28.8 percent completed the 400 mg arm against 63.7 percent on placebo.
JAMA Neurology - Review2012
Minocycline for acne vulgaris: efficacy and safety
39 randomised trials, 6,013 participants. Minocycline is effective for moderate to moderately severe inflammatory acne, with no evidence it is superior to other commonly used treatments. The review reports more severe adverse effects than doxycycline, an association with drug-induced lupus erythematosus at roughly 8.8 cases per 100,000 person-years rising with duration of use, and no support for the claim that extended-release preparations are safer.
Cochrane Database of Systematic Reviews
Frequently asked questions
Is minocycline a longevity drug?
No. The National Institute on Aging fed it to genetically heterogeneous mice and survival did not change in either sex. There is no human ageing data, and the largest human neurological trial found the treated group declined faster than placebo.
Why was an antibiotic tested for ageing at all?
Not for its antibiotic action. Minocycline crosses into the brain, suppresses microglial activation, and blocks caspase-dependent apoptosis in cell models, and it extended survival in mouse models of several neurological diseases. Neuroinflammation is a credible ageing mechanism, so it was a reasonable candidate.
Did it actually harm people?
In amyotrophic lateral sclerosis, yes. Across 412 patients, function on the ALSFRS-R declined at -1.30 units per month on minocycline against -1.04 on placebo, a significant difference, and the authors described the effect as harmful. That finding is specific to that disease and that dose, and it is the reason to treat the neuroprotection story with scepticism.
Does it still work for acne?
Yes, for moderate inflammatory acne, confirmed across 39 randomised trials. The Cochrane review found no evidence that it beats other commonly used treatments, and flagged a small but real association with drug-induced lupus that increases with duration of use.